FDA Grants Accelerated Approval for Zenbexus in Relapsed Multiple Myeloma

The FDA has granted accelerated approval to Zenbexus (iberdomide) for adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. Zenbexus is the first FDA-approved cereblon-modulating protein degrader (CELMoD) for this condition, offering a new treatment option. Continued approval is contingent upon verification of clinical benefit in confirmatory trials.